Mar. 19, 2014
Leading Pharma Entrepreneur Avi Meizler believes in Kadimastem!Investing around 1.7 million shekels in the Company
Yossi Ben Yosef, CEO of Kadimastem: “Mr. Meizler’s rich experience and many contacts in the global pharmaceutical industry, will make an important and significant contribution to the progress of Kadimastem and help us to achieve our strategic targets”
Ness Ziona Science Park, March 19, 2014: Kadimastem Ltd., which is developing technologies for drug screening and develop based on stem cells, announced today that it has signed an investment agreement with Mr. Avi Meizler, a strategic investor in the pharmaceutical industry. Under the terms of the agreement, Meizler will be appointed a member of the company’s Board of Directors. Kadimastem will allocate some 641 thousand shares, representing about 4.6% of the company’s capital at the price of NIS 2.7 per share (in return for about NIS 1.7 million).
In addition, Avi Meizler may invest a further amount of up to NIS 4 million in the company. Avi Meizler is a leading figure in the pharmaceutical industry in South America in general, and in Brazil in particular. With a group of partners, Meizler recently invested in Nasvax Ltd. UCB is a partner in his company, Meizler UCB Biopharma. Meizler is also the joint owner of Advantech, which engages in the development and commercialization of biological drugs. Mr. Meizler is one of the largest private investors in Brainsway, whose products he distributes in Brazil.
In addition, Mr. Meizler has invested in Therapix Bioscience and the life sciences company Nirolin. Yossi Ben Yosef, CEO of Kadimastem: “Mr. Meizler’s rich experience and many contacts in the global pharmaceutical industry, will make an important and significant contribution to the progress of Kadimastem and help us to achieve our strategic targets, both the clinical aspects of developing an innovative technological platform, and the business aspects of finding strategic partners, the future ability to raise capital, and examining mergers acquisitions.”